BTG Begins Sale of DC Bead(R) and Bead Block(R) Directly to Physicians

LONDON, UNITED KINGDOM--(Marketwired - Apr 1, 2015) - BTG plc

LSE: BTG

BTG begins sale of DC Bead^® and Bead Block^® directly to Physicians

London, UK, 1 April 2015: BTG plc (LSE: BTG), the specialist healthcare company, today began selling its drug-eluting bead and embolisation products, DC Bead^® and Bead Block^®, directly to customers in 11 European countries.

BTG has expanded its commercial presence in Europe in recent months by building an expert sales force to promote the approved uses of its products in major European markets. This team has been selling our radioembolisation product TheraSphere^® and starting today, will also sell DC Bead^® and Bead Block^®, our complementary interventional oncology products.

John Sylvester, Chief Commercial Officer for Interventional Medicine at BTG, said: "We're pleased to be supplying our beads and Therasphere^® products directly to healthcare professionals in Europe. BTG is investing in product innovation and clinical development to better serve specialist interventional oncology physicians. We're proud to be a leader in interventional medicine, moving medicines from major surgery to minor procedures and from the systemic to the local."

DC Bead^® and Bead Block^®, developed and manufactured by BTG, both received CE Mark approval in Europe in 2003. These products were previously sold in Europe by the Terumo Corporation under a contract that expired on 31 March 2015. BTG will be selling directly to hospitals in Austria, Belgium, France, Germany, Ireland, Italy, Netherlands, Portugal, Switzerland, Spain, and the UK.

Through the growth of its embolic bead products, the acquisitions of TheraSphere^® and EKOS Corporation, the US approval of Varithena^®, and the acquisition of interventional pulmonology company PneumRx earlier this year, BTG has become a leader in interventional medicine. Interventional medicine is a minimally invasive approach that relies on using medical imaging to deliver treatments precisely where they are needed in the body. This is a fast-growing area of medicine, driven by demand for better treatments and outcomes, advances in imaging techniques and product innovation. BTG is working with healthcare professionals across disciplines to realise the full potential of interventional medicine to treat patients.

About DC Bead^® and Bead Block^®

DC Bead^® is an embolic drug-eluting bead capable of loading and releasing chemotherapeutic agents for the treatment of hepatocellular carcinoma (HCC, a primary liver cancer) and liver metastases from colorectal and other cancers. Bead Block^® is an embolic device for embolising blood vessels of a variety of hypervascularised tumours and arteriovenous malformations and is most commonly used for the treatment of uterine fibroids and other benign (non-malignant) tumours. Both products are used in minimally invasive (non-surgical) procedures performed by an interventional radiologist.

About BTG
BTG is a growing international specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of liver tumours, severe blood clots, varicose veins and advanced emphysema, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: www.btgplc.com

For further information contact:

BTG
Chris Sampson, Director of Corporate Communications
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178

Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605

Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536